Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-HC01
- Development stage
- Phase 2
- Lead developer
- Beijing Dongfang Baitai Biotechnology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**EB-HC01** is an investigational allogeneic dual-target CAR-NK cell therapy described as a fixed 1:1 mixture of natural killer cells engineered with chimeric antigen receptors directed against human epidermal growth factor receptor 2 and carcinoembryonic antigen-related cell adhesion molecule 5. It is being evaluated following fludarabine and cyclophosphamide lymphodepletion for biomarker-selected unresectable or metastatic cholangiocarcinoma and other biliary tract cancers. The intended mechanism is antigen-specific recognition of HER2-positive and CEACAM5-positive tumor cells followed by CAR-NK-mediated cytotoxicity. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07641036))
- Other names
- EB-HC01 dual-target CARNK cellsEB-HC-01 dual-target CARNK cellsEB-HC 01 dual-target CARNK cellsEBHC-01EBHC01EBHC 01
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on EB-HC01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-HC01.